Research Summary
Dr. Habashi researches connective tissue disorders, particularly Marfan syndrome. She performed the initial studies demonstrating the effectiveness of losartan in mouse models of Marfan. She is currently evaluating the utility of additional medications for the treatment of this disorder.
Selected Publications
View all on PubMed
Gallo EM, Loch DC, Habashi JP, Calderon JF, Chen Y, Bedja D, van Erp C, Gerber EE, Parker SJ, Sauls K, Judge DP, Cooke SK, Lindsay ME, Rouf R, Myers L, ap Rhys CM, Kent KC, Norris RA, Huso DL, Dietz HC. “Angiotensin II-dependent TGF-β signaling contributes to Loeys-Dietz syndrome vascular pathogenesis.” J Clin Invest. 2014 Jan;124(1):448-60. doi: 10.1172/JCI69666. Epub 2013 Dec 20.
Liu D, Wang CJ, Judge DP, Halushka MK, Ni J, Habashi JP, Moslehi J, Bedja D, Gabrielson KL, Xu H, Qian F, Huso D, Dietz HC, Germino GG, Watnick T. “A Pkd1-Fbn1 genetic interaction implicates TGF-β signaling in the pathogenesis of vascular complications in autosomal dominant polycystic kidney disease.” J Am Soc Nephrol. 2014 Jan;25(1):81-91. doi: 10.1681/ASN.2012050486. Epub 2013 Sep 26.
Judge DP, Rouf R, Habashi J, Dietz HC. “Mitral valve disease in Marfan syndrome and related disorders.” J Cardiovasc Transl Res. 2011 Dec;4(6):741-7. doi: 10.1007/s12265-011-9314-y. Epub 2011 Aug 25. Review.
Habashi JP, Doyle JJ, Holm TM, Aziz H, Schoenhoff F, Bedja D, Chen Y, Modiri AN, Judge DP, Dietz HC. “Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism.” Science. 2011 Apr 15;332(6027):361-5. doi: 10.1126/science.1192152.
Holm TM, Habashi JP, Doyle JJ, Bedja D, Chen Y, van Erp C, Lindsay ME, Kim D, Schoenhoff F, Cohn RD, Loeys BL, Thomas CJ, Patnaik S, Marugan JJ, Judge DP, Dietz HC. “Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice.” Science. 2011 Apr 15;332(6027):358-61. doi: 10.1126/science.1192149.
Patient Ratings & Comments
The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.